Ondansetron Focus Care

Ondansetron, the active ingredient in Ondansetron Focus Care, is a 5‑HT3 receptor antagonist presented as an oral dosage form for oral use. It helps prevent nausea and vomiting caused by chemotherapy, radiotherapy, and postoperative recovery in adult patients.

GNH USA supplies Ondansetron Focus Care as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Ondansetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: helps prevent nausea and vomiting associated with radiation therapy. - Postoperative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures.

Ondansetron may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - QT interval prolongation - Severe allergic reaction (anaphylaxis) - Serotonin syndrome (rare) - Cardiac arrhythmia

When prescribing ondansetron, consider the following precautions: - Assess cardiac history: evaluate baseline ECG for QT prolongation risk. - Avoid concomitant use with other QT‑prolonging agents: monitor cardiac rhythm. - Use with caution in hepatic impairment: dose adjustment may be required. - Monitor for signs of hypersensitivity: discontinue if severe reaction occurs. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Ondansetron can interact with several medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): increased risk of cardiac arrhythmia. - Apomorphine: may cause severe hypotension and loss of consciousness. - Ritonavir: may increase ondansetron plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may raise plasma concentrations. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce effectiveness.